Clinical Trial Update: Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the gamma-secretase inhibitor RO4929097 in combination with gemcitabine in patients with advanced pancreatic cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 1 | Status: COMPLETED